Orton-Gillingham Classroom Educator Training—June 15-19, 2020 (attendance is mandatory for the week)

 

Course Fee: $525 (required texts run approximately an additional $100; optional texts run approximately another $150)

 

This training springboards into the Associate Level training but is a minimum 30-hour training. This training is designed for teachers working in classrooms or with small groups and is not intended for 1:1 instruction. Topics covered include: dyslexia and reading disorders; the OG
Approach; phonology and phonological awareness; handwriting; phonics for reading and spelling; the lesson plan; history and structure of the English language; beginning morphology; informal assessments and diagnostic-prescriptive teaching; and accuracy, automaticity, and fluency.

 

One hour of graduate credit is offered for the Classroom Educator Training through Baker University for $65; this is optional.

Orton-Gillingham Associate Level Training—June 15-26, 2020 (attendance is mandatory for the two weeks)

 

Course Fee: $1000 (required texts run approximately an additional $150; optional texts run approximately another $100)

 

The Associate Level training extends another week beyond the Classroom Educators training. This training is designed for 1:1 instruction.
Additional topics beyond the Classroom Educator training include: going further in-depth with the topics above; the lesson plan for 1:1; hands-on practice with a student (there will be a student that everyone will practice different parts of the lesson on); student profile; written
expression; reading comprehension; and the Academy’s philosophy, standards, and requirements.

 

Three hours of graduate credit are offered for the Associate Level Training through Baker University for $195; this is optional. This course does count as 3 hours toward Read to Succeed endorsement.

If you would like to register, please click on the Course Brochure below. Space is limited.

The training will still occur this summer although it might be done virtually due to COVID-19.